|
NIH Medical Rehabilitation Coordinating Committee (MRCC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, HRSA, SAMHSA
|
NICHD, CC, CSR, NCCIH, NCI, NEI, NHLBI, NIA, NIAMS, NIBIB, NIDCD, NIDDK, NIMH, NINDS, NINR
|
Pursuant to Public Law 101-613, the National Institutes of Health (NIH) Director established the Medical Rehabilitation Coordinating Committee. The Coordinating Committee makes recommendations to the National Institute of Child Health and Human Development (NICHD) Director and the Director of the National Center for Medical Rehabilitation Research with respect to the content of the research plan and activities that are carried out in conjunction with other components of NIH and with other Federal Government agencies.
|
|
NIH Psilocybin Research Speaker Series
|
Meeting/ Workshop
|
SAMHSA
|
NCI, CC, NCCIH
|
OverviewPsilocybin is the natural active compound found in more than 200 species of fungi, more commonly referred to as ”magic mushrooms.” Psilocybin is converted by the body to psilocin, which has hallucinogenic mind-altering properties. These naturally occurring mushrooms have been used anthropologically worldwide by indigenous cultures for centuries in the context of religious or spiritual healing ceremonies. Psilocybin is currently a Schedule I substance under the 1970 Controlled Substances Act (CSA). Schedule 1 classification defines chemicals or substances that, currently, have no accepted medical use and have a high potential for abuse. Advances in clinical trials, however, are researching psilocybin to treat cancer related depression, for example, and moreover for its potential medicinal application in treating a range of severe psychiatric disorders, such as: major depressive disorder, treatment resistant depression, post-traumatic stress disorder, opioid use disorder and other substance use disorders, as well as anorexia. To date, FDA granted two breakthrough therapy designations for psilocybin, one for treatment resistant depression in 2018, and a second for major depressive disorder in 2019.The Trans-NIH Integrative Medicine Course Organizing Committee is hosting a first-ever "NIH Psilocybin Research Speaker Series" from April 22-June 10, 2021. This time-sensitive, comprehensive Speaker Series will bring together the world’s leading experts, including scientists, physician-scientists, clinical psychologists, and oncologists. Additionally, in order to provide a comprehensive discussion, there will be representation from additional disciplines engaged in this rapidly growing field of research, including experts representing patient advocacy, law, government science policy, as well as regulatory policy.Objectives:• ; ; ; ; ; ; Education: provide time-sensitive and evidence-based scientific information, utilizing expert speakers from academia, government, and the community.• ; ; ; ; ; ; Research: assess the current state of the science, identify research gaps and opportunities, regarding future research needs for investigation among diverse research communities.For further information or questions about the Psilocybin Research Speaker Series, contact: Dan Xi, Ph.D., IM Course Director ([email protected]), ;Ann Berger, M.D. ([email protected]) and David Shurtleff, Ph.D. ([email protected]).The planning committee:Subject matter expert: Sean J. Belouin, Pharm.D. (SAMHSA/HHS) ;Trans-NIH Integrative Medicine Training Course Organizing Committee:;Ann Berger, M.D. (CC/NIH) ;Terry Moody, Ph.D. (NCI/NIH) ;David Shurtleff, Ph.D. (NCCIH/NIH) ;Dan Xi, Ph.D. (NCI/NIH) ;Farah Zia, M.D. (NCI/NIH);;
|
|
NIH Scientific Data Council for the Common Data Elements (CDE) Task Force (NIH CDE)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ
|
OD/DPCPSI/SGMRO, CC, CIT, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH, OD/OER, OD/OSP
|
The Common Data Elements (CDE) Task Force is charged by the National Institutes of Health (NIH) Scientific Data Council to advise it concerning how to improve the communication and coordination of NIH efforts to identify, develop, and promote the use of CDEs in NIH-supported research. Previously, as a working group under the aegis of the Trans-NIH BioMedical Informatics Coordinating Committee (BMIC), the group provided advice to the development of a CDE Repository that serves as a platform for searching, harmonizing, developing, and disseminating CDEs used by NIH Institutes and Centers; Task Force members continue to work with the National Library of Medicine (NLM) to improve this publicly available platform. The Task Force also maintains a web portal with information about NIH-supported CDE initiatives that are intended for use by NIH-funded researchers. The Task Force continues to take steps to encourage the use of CDEs by NIH-funded researchers, minimize overlap and redundancy in CDE initiatives, improve interoperability and compatibility between and among CDE initiatives and with other standards development activities (e.g., related to electronic health records), and assist NIH Institute and Center staff and researchers in identifying and using CDEs that are relevant to their projects.
|
|
NIH Training Advisory Committee (TAC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ
|
NIEHS, OD, NICHD, FIC, NCI, NHLBI, NHGRI, NIAMS, NIGMS, OD/OER
|
NIH is made up of 27 Institutes and Centers, each with a specific research mission, and each with its own training representative(s) who can answer questions about training and career development programs. I
|
|
NIH, HUD, CDC Housing and Health Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
ODP, NCI, NICHD, NIDDK, NHLBI, NIEHS, NIMHD, NINR, OD/DPCPSI/OBSSR
|
The collaboration between National Institutes Health (NIH), Centers for Disease Control and Prevention (CDC) and Department of Housing and Urban Development (HUD) is focused on identifying housing and health-related research resources, current activities and investments on this topic by each agency, and opportunities for collaboration to advance housing and health research. In 2020, a portfolio analysis was conducted of NIH and CDC applications and funded research pertaining to housing and health.
|
|
NIH-CDC-IDSA Guidelines for Treatment of HIV Related Opportunistic Infections Among Adults and Adolescents
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
CC, OD/DPCPSI/OAR
|
The National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and the Centers for Disease Control and Prevention (CDC) have developed guidelines for treatment of opportunistic infections (OIs) among adults and adolescents infected with human immunodeficiency virus (HIV). These guidelines are intended for clinicians and other health-care providers who care for HIV-infected adults and adolescents, including pregnant women; they complement companion guidelines for treatment of OIs among HIV-infected children and previously published guidelines for prevention of OIs in these populations.
|
|
NIH-FDA Interagency Clinical Outcome Assessments Working Group (ICOAWG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, CC, NHLBI, NIA, NIAMS, NICHD, NIDA, NIDDK, NIMH, NINDS, OD/DPCPSI
|
The Interagency Clinical Outcome Assessments Working Group (ICOA WG) works to foster the development, evaluation and qualification of Clinical Outcomes Assessments (COAs) for use in both medical product development and clinical research.
|
|
NIH-FDA Medical Device Research Interest Group and Medical Imaging and Data Resource Center (MDRIG)
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NIBIB, NCATS, NCI, NEI, NHLBI, NIA, NIAID, NICHD, NIDDK, NINR, OD/DPCPSI/ORIP, FIC, NIAMS, NIDA
|
The Medical Device Research Interest Group (MDRIG) meets quarterly to share information and ideas on supporting research throughout the development pipeline. Recent topics of interest include medical device clinical innovation and translation efforts, artificial intelligence and machine learning in imaging, early feasibility supplement for the Small Business Innovation Research (SBIR) grantees that would facilitate grantee Food and Drug Administration (FDA) meetings and communication in the formative years to increase appropriate planning during the development of their technologies toward FDA approval, and device digital twin technologies. Supported by NIBIB, MDRIG continues to meet four times per year.;In 2018, NIBIB hosted a trans-NIH workshop on gadolinium retention in patients after magnetic resonance imaging. Collaborators included the extramural medical imaging community. A subsequent widely referenced white paper identified gaps in knowledge and future areas for research. This workshop included FDA participation.;NIBIB also funded and hosted two large workshops on AI in Medical Imaging that included the FDA ; CMS and a wide swath of the extramural medical community. One was held in August 2018 and another in November 2019. These meetings also included NSF and NIST. In August 2020, NIBIB contracted the Medical Imaging ; Data Resource Center (MIDRC), which includes close FDA collaboration, in a project to aggregate medical images and develop AI-ready data and AI/ML algorithms for helping with the clinical management of COVID-19 patients and the pandemic in general.;As of this date, over 30,000 highly curated AI-ready COVID images are already available for public access and investigation, over 200,000 more are in the pipeline, and 24 algorithms are under development. An internal NIH advisory board monitors MIDRC along with NIBIB.
|
|
NIH/BARDA Antimicrobial Resistance (AMR) Diagnostic Challenge Working Group
|
Research Initiative
|
ASPR, FDA, CDC
|
NIAID
|
The Working Group designed, launched, and managed the largest USG Challenge competition of $20M through each of the three stages during the 5 years of the competition. The goal was to support the development of novel, innovative, rapid, point-of-need diagnostic in vitro assays to improve antibiotic stewardship and decrease the rapidly expanding AMR pandemic.
|
|
NIH/BMGF Collaboration - Point of Care Testing Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NIBIB, NCI, NIAID, NICHD
|
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) co-chairs the National Institutes of Health (NIH) Bill and Melinda Gates Foundation Working Group on Point of Care (POC) Diagnostics. This group of government and private partners is working to identify and collaborate on projects to develop diagnostic tests for low resource areas. One area of focus is to leverage resources for the development of a rapid POC diagnostic test for viral infections such as HIV or influenza. NIBIB hosted a working group session on March 30, 2017, that focused on patient access to health diagnostics. Ideas from this session were presented at the larger NIH-Gates Foundation meeting on June 30, 2017, hosted by NIH. In December 2021 the Tech Accelerator Challenge for Maternal Health (NTAC) was launched by NIH and the Gates Foundation. Through this Challenge, NIBIB offered $1,000,000 in prizes to spur and reward the development of low-cost, POC molecular, cellular, and/or metabolic sensing and diagnostic technologies to guide rapid clinical decision-making, improve patient outcomes, and ultimately prevent maternal morbidity and mortality. Awards will be made in the summer of 2022.;
|